Dark Defender: Narrative Will Continue to Shift In Favor of XRP. Here’s why
As uncertainty continues to weigh on digital asset market sentiment, crypto analyst Dark Defender has reiterated a technically grounded outlook on XRP that contrasts with growing concerns about a potential bear market.
In a February analysis supported by detailed monthly chart visuals, the analyst provided a structured interpretation of XRP’s price behavior, stating that recent volatility aligns with an anticipated corrective phase rather than signaling a broader trend reversal.
The commentary emphasizes long-term structural analysis over short-term price speculation, relying on an Elliott Wave framework that has guided expectations for several months.
Tracking the Monthly Wave 4 Development
According to Dark Defender, XRP has been progressing through a Monthly Wave 4 structure since mid-February. This corrective phase was mapped well in advance, with specific price zones identified as likely reaction points.
The analyst explains that the first leg of the correction, labeled Wave A, was projected toward the $1.88 region, a level that later corresponded with XRP’s decline to approximately $1.60 in April. This move was treated as a normal retracement within a broader bullish cycle rather than a breakdown in market structure.
The second phase, Wave B, unfolded as a recovery move. Dark Defender previously identified the $3.80 area as a key upside zone, and XRP’s subsequent advance toward $3.66 in July was cited as validation of that projection.
From this perspective, the rally was not interpreted as the start of a new impulsive wave but as a corrective rebound consistent with Wave B characteristics on a higher timeframe.
Completion of Wave C and Key Price Zone
The most recent development centers on Wave C, the final leg of the Monthly Wave 4 correction. Dark Defender states that the $1.88 level was once again targeted, forming a defined accumulation zone between $2.2222 and $1.8815. XRP’s return to this area is described as the technical completion of the corrective structure.
The analyst emphasizes that this outcome was anticipated and repeatedly communicated, reinforcing the importance of maintaining a consistent analytical framework during both advances and pullbacks.
Forward Outlook Beyond the Correction
With Monthly Wave 4 considered complete, Dark Defender’s analysis shifts toward the next phase of the cycle. The attached chart highlights a projected move toward the $5.85 region, derived from Fibonacci extensions and the anticipated Wave 5 advance.
The analyst maintains that this outlook remains intact as long as the broader structure holds, reiterating confidence that current conditions do not support a sustained bear market scenario.
The overall message underscores discipline and preparation, positioning the recent decline as a technical opportunity rather than a structural failure. Dark Defender concludes by reaffirming personal conviction in XRP’s trajectory, while noting that all views expressed are based on technical interpretation and not financial advice.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cyclical stocks always peak when they're “cheapest” — Citrini, the “chip influencer” who was the earliest to be bullish on AI hardware, is now quietly exiting
Citrini, once the most prominent bull in AI hardware, has now significantly reduced his semiconductor holdings and currently holds some short positions. He believes that the financing structure for AI infrastructure has shifted from tech giants' own cash flows to equity and debt markets, and that sentiment alone could sever the funding chain and impact fundamentals. Strategically, he is long Meta and short Google. Citrini also asserts that the bottleneck in AI pharmaceutical development is not computational power, but rather a "lack of monkeys."

New Zealand Dollar gains ground to near 0.5700 as RBNZ rate hike bets rise

Median survival prolonged by 5.7 months! Roche (RHHBY.US) lung cancer new drug wins in head-to-head trial, major catalyst for oncology business
Roche's investigational lung cancer drug divarasib extended patient survival by nearly six months compared to competing therapies in a late-stage clinical trial, promising to further strengthen the Swiss pharmaceutical company's oncology portfolio.
Global Aging Reshapes Equity and Bond Investment Logic? Pension "Longevity Bill" Accelerates Accumulation, Equities, Bonds, and Private Equity Welcome Massive Long-term Capital
As people live longer and birth rates decline, pension funds are required to allocate their assets for retirement periods that can last decades. Meanwhile, the number of workers contributing to these systems is decreasing.
